Compare ARDX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | MNKD |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2014 | 2004 |
| Metric | ARDX | MNKD |
|---|---|---|
| Price | $7.99 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $12.95 | $10.08 |
| AVG Volume (30 Days) | ★ 6.3M | 3.5M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $398,234,000.00 | $313,787,000.00 |
| Revenue This Year | $22.65 | $21.40 |
| Revenue Next Year | $31.33 | $25.03 |
| P/E Ratio | ★ N/A | $58.33 |
| Revenue Growth | ★ 58.12 | 17.43 |
| 52 Week Low | $3.21 | $3.38 |
| 52 Week High | $8.17 | $6.51 |
| Indicator | ARDX | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 57.24 |
| Support Level | $6.73 | $5.03 |
| Resistance Level | $7.25 | $5.68 |
| Average True Range (ATR) | 0.57 | 0.27 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 89.03 | 59.80 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.